Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Hung-Ling HuangInn-Wen Chong

Abstract

Weekly rifapentine and isoniazid (3HP) is gaining popularity for latent tuberculosis infection treatment because of its short course and high completion rate. Prior to widespread use, comprehensive 3HP treatment assessment covering an all-age population is essential. Participants receiving ≥1 3HP dose from September 2014 to December 2019 were stratified into elderly (≥65 years), middle-aged (>35 & <65 years), and younger (≤35 years) age groups. This study investigated the impact of age on treatment outcome, particularly systemic drug reactions (SDRs) and 3HP discontinuation. Overall, 134 of 579 (23.1%) participants were elderly. The completion rate was 83.1% overall and was highest and lowest in the younger group (94.5%) and elderly (73.9%) group, respectively. However, the 3HP discontinuation rate was not significantly different among the 3 groups in multivariate logistic regression analysis. In total, 362 (62.5%) participants experienced 1 or more adverse drug reactions (ADRs), of which 38 (10.5%) and 98 (27.1%) required temporary and permanent treatment interruption, respectively. The SDR risk was 11.2% in overall and 17.1% in the middle-aged group, 3.04-fold higher than that in the elderly group (P = .025). This finding was...Continue Reading

References

Aug 1, 1981·Clinical Pharmacology and Therapeutics·C A NaranjoD J Greenblatt
Feb 14, 2006·American Journal of Respiratory and Critical Care Medicine·Mauro SchechterRichard E Chaisson
May 23, 2006·Journal of Behavioral Medicine·Jennifer E GrahamJanice K Kiecolt-Glaser
Dec 6, 2008·World Journal of Gastroenterology : WJG·Kazuto Tajiri, Yukihiro Shimizu
Jul 8, 2011·The New England Journal of Medicine·Neil A MartinsonRichard E Chaisson
Dec 14, 2011·The New England Journal of Medicine·Timothy R SterlingUNKNOWN TB Trials Consortium PREVENT TB Study Team
Nov 10, 2012·Current Medical Research and Opinion·Anne M BaciewiczTimothy H Self
Apr 24, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy R SterlingUNKNOWN Tuberculosis Trials Consortium
Mar 13, 2016·BMC Infectious Diseases·Rachel Byng-Maddick, Mahdad Noursadeghi
May 20, 2016·Clinical Interventions in Aging·Nibu Parameswaran NairLuke R Bereznicki
Oct 5, 2016·Clinical Medicine : Journal of the Royal College of Physicians of London·Jamie J Coleman, Sarah K Pontefract
Dec 30, 2016·Transplant International : Official Journal of the European Society for Organ Transplantation·Jacques SimkinsJose F Camargo
Apr 13, 2017·Aging and Disease·Massimo De MartinisLia Ginaldi
Jun 3, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Amy L SandulChristine S Ho
Nov 9, 2017·Annals of Internal Medicine·Robert BelknapUNKNOWN TB Trials Consortium iAdhere Study Team
Jun 19, 2018·American Journal of Preventive Medicine·Gibril J NjieAndrey S Borisov
Jun 9, 2019·Journal of Clinical Medicine·Meng-Rui LeeInn-Wen Chong
Nov 16, 2019·The Annals of Pharmacotherapy·Ramara E WalkerAndrea M Pallotta

❮ Previous
Next ❯

Citations

Mar 8, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hung-Ling HuangInn-Wen Chong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.